Treadwell Therapeutics Announces The Closing Of A $91 Million Series B Financing
11/18/21, 7:00 AM
Location
new yorkMoney raised
$91 million
Round Type
series b
Treadwell Therapeutics ("Treadwell"), a clinical-stage biotechnology company developing novel, cross-modality medicines for unmet needs in cancer, today announced the closing of an oversubscribed Series B financing, which raised more than $91 million. The financing was led by Sino Biopharmaceutical Limited and 3W Fund Management Limited ("3W Fund") and included new investors including renowned culture entrepreneur and investor Mr. Adrian Cheng, Prosperous Alliance, Alpha Win Capital, Fortune Ocean Growth Fund L.P. and, along with existing investors TIO Bioventures, and other undisclosed institutional and individual investors.
Company Info
Location
new york, new york, united states
Additional Info
Treadwell Therapeutics is a science driven, clinical-stage multi-modality oncology company developing first-in-class and best-in-class medicines to address unmet needs in patients with cancer. Founded by a cadre of pre-eminent scientific luminaries, including Dr. Tak W. Mak, the Company's robust, internally developed pipeline includes a first-in-class PLK4 kinase inhibitor, CFI-400945 and a best-in-class TTK inhibitor, CFI-402257, and CFI-402411, an oral immunomodulatory kinase inhibitor with activity toward HPK1. Treadwell also has a robust pre-clinical pipeline with multiple biologic and next generation TCR based autologous cell therapy programs. For more information, please visit www.treadwelltx.com.